Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas

Critical Reviews in Oncology/Hematology

Volumn 99, Issue , 2016, Pages 214-227

  Zinzani, Pier Luigi ^a   Bonthapally, Vijayveer ^b   Huebner, Dirk ^b   Lutes, Richard ^b   Chi, Andy ^b   Pileri, Stefano ^c,d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Adult T cell leukemia lymphoma; Anaplastic large cell lymphoma; Angioimmunoblastic T cell lymphoma; Belinostat; Brentuximab vedotin; Peripheral T cell lymphoma; Pralatrexate; Romidepsin

Indexed keywords

ANTINEOPLASTIC AGENT; BELINOSTAT; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CISPLATIN; CRIZOTINIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MESNA; METHYLPREDNISOLONE; PLATINUM COMPLEX; PRALATREXATE; PREDNISONE; ROMIDEPSIN; VINCRISTINE;

B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COMORBIDITY; DRUG APPROVAL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; HUMAN; LARGE CELL LYMPHOMA; OUTCOME ASSESSMENT; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; REVIEW; RISK FACTOR; TREATMENT DURATION; ADULT; DRUG EFFECTS; DRUG RESISTANCE; LYMPHOMA, T-CELL, PERIPHERAL; SALVAGE THERAPY; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY;

EID: 84959466019     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.12.016     Document Type: Review

References (121)

1. ADCETRIS® (brentuximab vedotin) for injection Full Prescribing Information 2015, Seattle Genetics, Inc., Bothell, WA, USA, (accessed 05.02.15.). http://www.adcetris.com/pdf/ADCETRIS-brentuximab-vedotin-Prescribing-Information.pdf.
2. ADCETRIS® 50 mg powder for concentrate for solution for infusion Summary of Product Characteristics 2015, Takeda Pharma A/S, Roskilde, Denmark, (accessed 05.02.15.). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002455/WC500135055.pdf.
3. Advani R., Horwitz S., Zelenetz A., Horning S.J. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk. Lymphoma 2007, 48(3):521-525. 10.1080/10428190601137658.
4. Ahn H.K., Kim S.J., Hwang D.W., et al. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma. Invest. New Drugs 2013, 31(2):469-472. 10.1007/s10637-012-9889-4.
5. Al-Kali A., Gandhi V., Ayoubi M., et al. Forodesine: review of preclinical and clinical data. Future Oncol. 2010, 6(8):1211-1217. 10.2217/fon.10.83.
6. Anne M., Sammartino D., Barginear M.F., et al. Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther. 2013, 6:1613-1624. 10.2147/ott.s30773.
7. Arkenau H.T., Chong G., Cunningham D., et al. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the royal marsden hospital experience. Haematologica 2007, 92(2):271-272. 10.3324/haematol.10737.
8. BELEODAQ® (belinostat) for injection, for intravenous administration Full prescribing information. Revised: 7/2014 2015, Spectrum Pharmaceuticals, Inc., Irvine, CA, USA, (accessed 05.02.15.). http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206256lbl.pdf.
9. Barr P.M., Li H., Spier C., et al. Phase II Intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108. J. Clin. Oncol. 2015, 33(21):2399-2404. 10.1200/JCO. 2014.60.6327.
10. Bartlett N.L., Chen R., Fanale M.A., et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J. Hematol. Oncol. 2014, 7:24. 10.1186/1756-8722-7-24.
11. Bodiford A., Bodge M., Talbott M.S., et al. Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma. Onco Targets Ther. 2014, 7:1971-1977. 10.2147/ott.s59269.
12. Campath® (alemtuzumab) Injection for intravenous use. Full prescribing information. Revised: 9/ 2015, Genzyme Corporation, Cambridge, MA, USA, (accessed 05.02.15.). http://www.campath.com/pdfs/2014-09-Campath_US_PI.pdf.
13. Chen X., Soma L.A., Fromm J.R. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin. Onco Targets Ther. 2013, 7:45-56. 10.2147/ott.s39107.
14. Chihara D., Ito H., Katanoda K., et al. Increase in incidence of adult T-cell leukemia/lymphoma in non-endemic areas of Japan and the United States. Cancer Sci. 2012, 103(10):1857-1860. 10.1111/j.1349-7006.2012.02373.x.
15. Coiffier B., Pro B., Prince H.M., et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J. Clin. Oncol. 2012, 30(6):631-636. 10.1200/JCO.2011.37.4223.
16. Coiffier B., Pro B., Prince H.M., et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J. Hematol. Oncol. 2014, 7(1):11. 10.1186/1756-8722-7-11.
17. Damaj G., Gressin R., Bouabdallah K., et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J. Clin. Oncol. 2013, 31(1):104-110. 10.1200/JCO.2012.43.7285.
18. Dang N.H., Pro B., Hagemeister F.B., et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br. J. Haematol. 2007, 136(3):439-447. 10.1111/j.1365-2141.2006.06457.x.
19. Dearden C., Johnson R., Pettengell R., et al., 2015. British Committee for Standards in Haematology (BCSH) guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Updated August 2013. Available at: . (accessed 06.02.15.). http://www.bcshguidelines.com.
20. Dincol D., Buyukcelik A., Dogan M., et al. Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP. Med. Oncol. 2010, 27(3):942-945. 10.1007/s12032-009-9313-x.
21. Dong M., He X.H., Liu P., et al. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma. Med. Oncol. 2013, 30(1):351. 10.1007/s12032-012-0351-4.
22. Dreyling M., Thieblemont C., Gallamini A., et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann. Oncol. 2013, 24(4):857-877. 10.1093/annonc/mds643.
23. Dueck G., Chua N., Prasad A., et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010, 116(19):4541-4548. 10.1002/cncr.25377.
24. Duvic M., Kuzel T.M., Dang N.H., et al. A dose finding lead-in study of E7777 (diphtheria toxin fragment-interleukin-2 fusion protein) in persistent or recurrent cutaneous T-cell lymphoma (CTCL). Blood 2014, 124(21). abstract 3097.
25. Emmanouilides C., Colovos C., Pinter-Brown L., et al. Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin. Lymphoma 2004, 5(1):45-49. 10.3816/CLM.2004.n.009.
26. Enblad G., Hagberg H., Erlanson M., et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004, 103(8):2920-2924. 10.1182/blood-2003-10-3389.
27. Evens A.M., Rosen S.T., Helenowski I., et al. A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. Br. J. Haematol. 2013, 163(1):55-61. 10.1111/bjh.12488.
28. FOLOTYN® (pralatrexate injection) Solution for intravenous injection. Full prescribing information. Revised: 5/2012 2012, Allos Therapeutics, Inc., Westminster, CO, USA, (accessed 06.02.15.). http://www.folotyn.com/sites/default/files/pdf/folotyn.pdf.
29. Fanale M.A., Hagemeister F.B., Fayad L., et al. A Phase I trial of alisertib plus romidepsin for relapsed/refractory aggressive B- and T-Cell lymphomas. Blood 2014, 124(21). abstract 1744.
30. Foss F.M., Zinzani P.L., Vose J.M., et al. Peripheral T-cell lymphoma. Blood 2011, 117(25):6756-6767. 10.1182/blood-2010-05-231548.
31. Foss F.M., Sjak-Shie N., Goy A., et al. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk. Lymphoma 2013, 54(7):1373-1379. 10.3109/10428194.2012.742521.
32. Foss F., Coiffier B., Horwitz S., et al. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomarkers Res. 2014, 2:16. 10.1186/2050-7771-2-16.
33. Foss F., Advani R., Duvic M., et al. A Phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br. J. Haematol. 2015, 168(6):811-819. 10.1111/bjh.13222.
34. Friedberg J.W., Mahadevan D., Cebula E., et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J. Clin. Oncol. 2014, 32(1):44-50. 10.1200/JCO.2012.46.8793.
35. Gambacorti-Passerini C., Messa C., Pogliani E.M. Crizotinib in anaplastic large-cell lymphoma. N. Engl. J. Med. 2011, 364(8):775-776. 10.1056/nejmc1013224.
36. Gambacorti-Passerini C., Horibe K., Braiteh F., et al. Safety and clinical activity of crizotinib in patients with ALK-rearranged hematologic malignancies. Blood 2013, 122(21). abstract 4342.
37. Gkotzamanidou M., Papadimitriou C.A. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation. Crit. Rev. Oncol. Hematol. 2014, 89(2):248-261. 10.1016/j.critrevonc.2013.08.016.
38. Goh Y.-T., Hwang W.Y.K., Diong C.P., et al. A Phase 2 Study of panobinostat (PAN) in combination with bortezomib (BTZ) in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) or NK/T-cell lymphoma (NKL). Blood 2014, 124(21). abstract 503.
39. Gravina G., Senapedis W., McCauley D., et al. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J. Hematol. Oncol. 2014, 7:85. 10.1186/s13045-014-0085-1.
40. Guenova E., Hoetzenecker W., Rozati S., et al. Novel therapies for cutaneous T-cell lymphoma: what does the future hold?. Expert Opin. Investig. Drugs 2014, 23(4):457-467. 10.1517/13543784.2014.876407.
41. Hopfinger G., Nösslinger T., Lang A., et al. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Ann. Hematol. 2014, 93(3):459-462. 10.1007/s00277-014-2009-0.
42. Horwitz S., O'Connor O., Jurczak W., et al. Belinostat in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) subtype angioimmunoblastic T-cell lymphoma (AITL): results from the pivotal BELIEF trial. Hematol. Oncol. 2013, 31(Suppl. 1):147-148. (abstract 153). 10.1002/hon.2057.
43. Horwitz S.M., Advani R.H., Bartlett N.L., et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014, 123(20):3095-3100. 10.1182/blood-2013-12-542142.
44. Horwitz S.M., Porcu P., Flinn I., et al. Duvelisib (IPI-145), a phosphoinositide-3-kinase-δ,γ inhibitor, shows activity in patients with relapsed/refractory T-cell lymphoma. Blood 2014, 124(21). abstract 803.
45. ISTODAX® (romidepsin) for injection Full prescribing information. Revised: 10/2014 2015, Celgene Corporation, Summit, NJ, USA, (accessed 05.02.15.). http://www.istodax.com/pdfs/ISTODAX_PackageInsert_11192009.pdf.
46. Ishida T., Joh T., Uike N., et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J. Clin. Oncol. 2012, 30(8):837-842. 10.1200/JCO.2011.37.3472.
47. Jaccard A., Gachard N., Marin B., GELA and GOELAMS Intergroup, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011, 117(6):1834-1839. 10.1182/blood-2010-09-307454.
48. Jain S., Jirau-Serrano X., Palermo F.C., et al. Novel imaging modalities in innovative xenograft mouse model of T-cell lymphoma confirm marked synergy of romidepsin and pralatrexate. Blood 2012, 120(21). abstract 2758.
49. Karlin L., Coiffier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin. Hematol. 2014, 51(1):25-34. 10.1053/j.seminhematol.2013.11.001.
50. Karube K., Aoki R., Nomura Y., et al. Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol. Int. 2008, 58(2):89-97. 10.1111/j.1440-1827.2007.02195.x.
51. Khot A., Dickinson M., Prince H.M. Romidepsin for peripheral T-cell lymphoma. Expert Rev. Hematol. 2013, 6(4):351-359. 10.1586/17474086.2013.814833.
52. Khot A., Dickinson M., Prince H.M. Panobinostat in lymphoid and myeloid malignancies. Expert Opin. Investig. Drugs 2013, 22(9):1211-1223. 10.1517/13543784.2013.815165.
53. Kim S.J., Kim K., Kim B.S., et al. Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study. Ann. Oncol. 2009, 20(2):390-392. 10.1093/annonc/mdn726.
54. Kuruvilla J., Byrd J.C., Flynn J.M., et al. The oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) demonstrates broad and durable clinical activity in relapsed/refractory non Hodgkin's lymphoma (NHL). Blood 2014, 124(21). abstract 396.
55. Kwong Y.L., Kim W.S., Lim S.T., et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012, 120(15):2973-2980. 10.1182/blood-2012-05-431460.
56. López A., Gutiérrez A., Palacios A., et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur. J. Haematol. 2008, 80(2):127-132. 10.1111/j.1600-0609.2007.00996.x.
57. Lunning M.A., Horwitz S. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?. Curr. Treat. Options Oncol. 2013, 14(2):212-223. 10.1007/s11864-013-0232-x.
58. Mak V., Hamm J., Chhanabhai M., et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J. Clin. Oncol. 2013, 31(16):1970-1976. 10.1200/JCO. 2012.44.7524.
59. Malik S.M., Liu K., Qiang X., et al. Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. Clin. Cancer Res. 2010, 16(20):4921-4927. 10.1158/1078-0432.ccr-10-1214.
60. Manfredi M.G., Ecsedy J.A., Chakravarty A., et al. Characterization of alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin. Cancer Res. 2011, 17(24):7614-7624. 10.1158/1078-0432.ccr-11-1536.
61. Mayer J., Korístek Z., Vásová I., et al. Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma. Bone Marrow Transplant. 1999, 23(5):413-419.
62. Mey U.J., Orlopp K.S., Flieger D., et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest. 2006, 24(6):593-600. 10.1080/07357900600814490.
63. Morschhauser F., Fitoussi O., Haioun C., et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur. J. Cancer 2013, 49(13):2869-2876. 10.1016/j.ejca.2013.04.029.
64. Morton L.M., Wang S.S., Devesa S.S., et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107(1):265-276. 10.1182/blood-2005-06-2508.
65. Mossé Y.P., Lim M.S., Voss S.D., et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet. Oncol. 2013, 14(6):472-480. 10.1016/s1470-2045(13)70095-0.
66. National Cancer Institute, 2015. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Non-Hodgkin's Lymphomas. Version 2.2015. Available at: . (accessed 10.11.15.). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.
67. National Cancer Institute, 2015. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Multiple Myeloma. Version 2.2016. Available at: . (accessed 10.11.15.). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#sire.
68. Ng M., Waters J., Cunningham D., et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br. J. Cancer 2005, 92(8):1352-1357. 10.1038/sj.bjc.6602514.
69. O'Connor O.A., Horwitz S., Hamlin P., et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J. Clin. Oncol. 2009, 27(26):4357-4364. 10.1200/JCO.2008.20.8470.
70. O'Connor O.A., Pro B., Pinter-Brown L., et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J. Clin. Oncol. 2011, 29(9):1182-1189. 10.1200/JCO.2010.29.9024.
71. O'Connor O.A., Horwitz S., Masszi T., et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J. Clin. Oncol. 2015, 33(23):2492-2499. 10.1200/JCO.2014.59.2782.
72. ONTAK® (denileukin diftitox) injection for intravenous infusion Full prescribing information. Revised: August 2011 2014, Eisai Inc., Woodcliffe Lake, NJ, USA, (accessed 17.07.14.). http://us.eisai.com/wps/wcm/connect/eisai/Home/resources/ffc697804fdfb662a249a2c7586bf6dd/OntakPI.pdf.
73. Ogura M., Tsukasaki K., Nagai H., et al. Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignanciese. Cancer Sci. 2012, 103(7):1290-1295. 10.1111/j.1349-7006.2012.02287.x.
74. Ogura M., Tobinai K., Hatake K., et al. Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 2014, 105(7):840-846. 10.1111/cas.12435.
75. Ogura M., Ishida T., Hatake K., et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J. Clin. Oncol. 2014, 32(11):1157-1163. 10.1200/JCO.2013.52.0924.
76. Park B.B., Kim W.S., Suh C., et al. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann. Hematol. 2015, 94(11):1845-1851. 10.1007/s00277-015-2468-y.
77. Perrone G., Corradini P. Autologous stem cell transplantation for T-cell lymphomas. Semin. Hematol. 2014, 51(1):59-66. 10.1053/j.seminhematol.2013.11.002.
78. Perrone G., Farina L., Corradini P. Current state of art for transplantation paradigms in peripheral T-cell lymphomas. Expert Rev. Hematol. 2013, 6(4):465-474. 10.1586/17474086.2013.814437.
79. Phillips A.A., Fields P., Hermine O., et al. Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator's choice of chemotherapy in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL). J. Clin. Oncol. 2014, 32(Suppl. 5s). abstract TPS8622.
80. Piekarz R.L., Frye R., Prince H.M., et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011, 117(22):5827-5834. 10.1182/blood-2010-10-312603.
81. Poole R.M. Belinostat: first global approval. Drugs 2014, 74(13):1543-1554. 10.1007/s40265-014-0275-8.
82. Pro B., Advani R., Brice P., et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J. Clin. Oncol. 2012, 30(18):2190-2196. 10.1200/JCO.2011.38.0402.
83. Pro B., Advani R.H., Brice P., et al. Three-year survival results from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 2013, 122(21). abstract 1809.
84. Pro B., Advani R.H., Brice P., et al. Four-year survival data from an ongoing pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 2014, 124(21). abstract 3095.
85. REVLIMID® (lenalidomide) capsules, for oral us Full prescribing information. Revised: 9/2014 2015, Celgene Corporation, Summit, NJ, USA, (accessed 10.02.15.). http://www.revlimid.com/wp-content/uploads/2013/11/PI.pdf.
86. Ravandi F., Aribi A., O'Brien S., et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J. Clin. Oncol. 2009, 27(32):5425-5430. 10.1200/JCO. 2009.22.6688.
87. Redaelli S., Farina F., Stasia A., et al. High response rates to crizotinib in advanced, chemoresistant ALK+ lymphoma patients. Blood 2013, 122(21). abstract 368.
88. Reddy N.M., Evens A.M. Chemotherapeutic advancements in peripheral T-cell lymphoma. Semin. Hematol. 2014, 51(1):17-24. 10.1053/j.seminhematol.2013.11.006.
89. Ribrag V., Caballero D., Fermé C., et al. Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. Haematologica 2013, 98(3):357-363. 10.3324/haematol.2012.069757.
90. Sallah S., Wan J.Y., Nguyen N.P. Treatment of refractory T-cell malignancies using gemcitabine. Br. J. Haematol. 2001, 113(1):185-187. 10.1046/j.1365-2141.2001.02743.x.
91. Savage K.J., Horwitz S.M., Zinzani P.L., et al. Safe and effective treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) and low baseline platelet counts with belinostat. Blood 2014, 124(21). abstarct 3075.
92. Schmitz N., Wu H.S., Glass B. Allogeneic transplantation in T-cell lymphomas. Semin. Hematol. 2014, 51(1):67-72. 10.1053/j.seminhematol.2013.11.010.
93. Sharaiha R.Z., Lebwohl B., Reimers L., et al. Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973-2008. Cancer 2012, 118(15):3786-3792. 10.1002/cncr.26700.
94. Shimanovsky A., Dasanu C.A. Pralatrexate: evaluation of clinical efficacy and toxicity in T-cell lymphoma. Expert Opin. Pharmacother. 2013, 14(4):515-523. 10.1517/14656566.2013.770474.
95. Siddiqi T., Frankel P., Ruel C., et al. Phase 1 study of MLN8237, an aurora kinase A (AURKA) inhibitor, combined with vorinostat, a histone deacetylase (HDAC) inhibitor, in lymphoid malignancies. Blood 2014, 124(21). abstract 4483.
96. Sirotnak F.M., DeGraw J.I., Colwell W.T., et al. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother. Pharmacol. 1998, 42(4):313-318. 10.1007/s002800050823.
97. Subramaniam J.M., Whiteside G., McKeage K., et al. Mogamulizumab: first global approval. Drugs 2012, 72(9):1293-1298. 10.2165/11631090-000000000-00000.
98. Swerdlow S.H., Campo E., Harris N.L., et al. Pathology and genetics of tumours of hematopoietic and lymphoid tissues. World Health Organization Classification of Tumours 2008, International Agency for Research on Cancer Press, Lyon, France, (Chapter 11) 270-299367.
99. TREANDA™ (bendamustine HCL) injection Full prescribing information. Revised: 9/2013 2015, Teva Pharmaceuticals USA, Inc., North Wales, PA, USA, (accessed 06.02.15.). http://www.treanda.com/PDF/TREANDA_final_PI.pdf.
100. Toumishey E., Prasad A., Dueck G., et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer 2015, 121(5):716-723. 10.1002/cncr.29103.
101. Velasquez W.S., Cabanillas F., Salvador P., et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988, 71(1):117-122.
102. Velasquez W.S., McLaughlin P., Tucker S., et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J. Clin. Oncol. 1994, 12(6):1169-1176.
103. Vose J., Armitage J., Weisenburger D., International T-Cell Lymphoma Project International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 2008, 26(25):4124-4130. 10.1200/JCO.2008.16.4558.
104. Wang E.S., O'Connor O., She Y., et al. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk. Lymphoma 2003, 44(6):1027-1035. 10.1080/1042819031000077124.
105. Weidmann E., Hess G., Chow K.U., et al. A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk. Lymphoma 2010, 51(3):447-455. 10.3109/10428190903580402.
106. Wilson W.H., Bryant G., Bates S., et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 1993, 11(8):1573-1582.
107. Winkler D.G., Faia K.L., DiNitto J.P., et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem. Biol. 2013, 20(11):1364-1374. 10.1016/j.chembiol.2013.09.017.
108. XALKORI® (crizotinib) capsules, oral Full prescribing information. Revised: 5/2014 2015, Pfizer Labs, New York City, NY, USA, (accessed 06.02.15.). http://labeling.pfizer.com/showlabeling.aspx?id=676.
109. Yamaguchi M., Suzuki R., Kwong Y.L., et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008, 99(5):1016-1020. 10.1111/j.1349-7006.2008.00768.x.
110. Yamaguchi M., Kwong Y.L., Kim W.S., et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group studye. J. Clin. Oncol. 2011, 29(33):4410-4416. 10.1200/JCO.2011.35.6287.
111. Yamamoto K., Utsunomiya A., Tobinai K., et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 2010, 28(9):1591-1598. 10.1200/JCO. 2009.25.3575.
112. Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 2010, 363(19):1812-1821. 10.1056/nejmoa1002965.
113. ZOLINZA® (vorinostat) Capsules Full prescribing information. Revised: 04/2013 2015, Patheon, Inc., Ontario, Canada, (accessed 05.02.15.). http://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_pi.pdf.
114. Zelenetz A.D., Hamlin P., Kewalramani T., et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann. Oncol. 2003, 14:i5-10. 10.1093/annonc/mdg702.
115. Zinzani P.L., Magagnoli M., Bendandi M., et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann. Oncol. 1998, 9(12):1351-1353.
116. Zinzani P.L., Baliva G., Magagnoli M., et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J. Clin. Oncol. 2000, 18(13):2603-2606.
117. Zinzani P.L., Alinari L., Tani M., et al. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 2005, 90(5):702-703.
118. Zinzani P.L., Venturini F., Stefoni V., et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann. Oncol. 2010, 21(4):860-863. 10.1093/annonc/mdp508.
119. Zinzani P.L., Pellegrini C., Broccoli A., et al. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk. Lymphoma 2011, 52(8):1585-1588. 10.3109/10428194.2011.573031.
120. Zinzani P.L., Corradini P., Gallamini A., et al. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leuk. Lymphoma 2012, 53(5):789-795. 10.3109/10428194.2011.629701.
121. Zinzani P.L., Coiffier B., Radford J., et al. A phase II open-label, multi-center study of anti-CCR4 monoclonal antibody mogamulizumab (KW-0761) in patients with previously treated peripheral T-cell lymphoma (PTCL). Blood 2014, 124(21). abstract 1763.